Member Info for RorkesDrift

Anyone got a link to it. Ich nich sprich dich

Great sentiment ruined by use of the magic calculator. It is a cumulative dose of an inert drug. The numbers that matter are cumulative dose hitting the tumour which is a consequence of the cumulative dose converted. Upgrading from the Fisher Price approach required.

Hopefully numerous patients from C1 remain on treatment because

A) side effects remain low

B) Tumour remains in check or in retreat.

Patients entering trial benefit from this new drug - tops any fantasy magic calculator motivated by a pathological need to ramp - suspect someone's average is a bit high.

Ava6000 at the very least derisks this nvestment. For dox longer treatment period also unlocks value - effi any data to date suggests this will happen but also higher rates of disease regression

I think the new product announcements will leverage the TME vs systemic circulation. By avoiding high levels of systemic exposure the most toxic warheads can be used - the pK data presented so far establishes this potential especially if half life can be extended.

Unbreaded can you post the reference please. You are right that a comparison between TME for straight dox and ava6000 would be more use than cf the and plasma but the later is not useless. There are warheads more toxic than dox. You then have to consider outcomes - ava6000 appears to have some efficacy. Refine the posology (some have been saying that before even first human treated) and the indication and we have what may be a brand new approach to treatment. Add in half life extenders.

Meanwhile I'm going off to read a posting from one camper about another camper who both wouldn't know pK from pH but feel qualified to post several time per day. Have you read the one about human meat substitutes.....

Bump.

Even if it does work to release a ahead in arthritic joints that could be a caution or contraindication. In terms of a new market I'd just ask is there an unmet need - clearly toxicity is something that's a problem in oncology but don't know about arthritis

From memory mid fap tumours were able to convert - the impact on tumour was more linked to dox sensitivity. Implication is use a different war head and increase dosing frequency and or extend half life and you start navigating R&D by disease rather than drug.

Several patients in the 3w study continued to receive drug and respond - great news for everyone. So we can also expect to see that picture evolve outside of the 2w dosing.

The 2w cohort could be expected to respond - hopefully all dox sensitive. Therefore, would be logical two further reports - the p1a outcomes and the extension of trt outcomes. The start of p2 will occur inbetween unless we go to a weekly cohort.....

Https://aptamergroup.com/agreement-to-explore-optimer-vehicles-for-targeted-delivery-of-sirna/

It does.

Id have like to see the results stratified into normaly treated with dox or not.

Could present as a classic 2x2 matrix - high / low fap vs. Dox sensitive / insensitive.

Would highlight the warhead is the key bit - albeit posology needs to be tweaked. Take the normal warhead, attach to precision, identify optimum dosing, print money.

Ive booked £1.37 day off as a holiday

Hang on. You think our chairman would lend a hand but probably has them full with his own issue.

If that were true thrn he wouldnt need 4M options all which genetate him a massive payoff even at todays SP.

Board needs to realign benefits for him, CFO and if we have one thats awake Chairman to share holder value. Forva start ATH would be minimum for any new options

What progress has been made in the last 12 months towards commercialising affimers.

Sorry. Did i say months. I meant years.

Both the remaining members have been in touch and offered to let me join. I have to provide my own pom poms but i get a free magic calculatorband can post anything i like on twitter even if it looks like the working out of a five year old

20p to ATM and continue to hold. I think P1 results vindicate this - only lose or make if you sell and given the data the argument favouring eventual RoI from here looks better than it ever has and thst included the lft jam tomorrow promises

End of 40 day silence coming up. Turnip and no Hope have sight of comms. Share price......

From my persoective we have information coming out that shows the board made a mess of it and chose a path that destroyed value. This is why SP remains where it us despite what i think are fantastic P1 results. At some point sentiment about avct will change but only on rns that detail value being realised. Hard to take but ive been here across price of

Optimers direct competitor to affimers. Would be nice to have Unilver onboard.....

https://markets.ft.com/data/announce/detail?dockey=1323-16411110-6JKC2FR5UKO721KJSJ4RI687G2

I agree. Who cares what McPumpy writes. That includes those pointing out thatba monkey with a pin would have more success and those who insist on posting "Myles say..." post as if they were gold dust.

End of the day what he says and does are two different things and only the gullible would pay any attention and are funding any success he has through their losses - every seller needs a buyer. QED